CommercialPrior AuthMedium impact
Point32Health medical drug program updates
Harvard Pilgrim Health Care·Neurology, Oncology, Dermatology +2 more·Prior Authorization
Effective date
Aug 1, 2026
We identified it
Aug 4, 2026
Summary
Point32Health updated prior authorization requirements and coverage criteria for 7 medical benefit drugs across multiple plans, effective August 1 and October 1, 2026. Key changes include: Vyjuvek now covers all ages (not age-restricted), Zolgensma requires documentation of no prior gene therapy, Epioxa no longer requires prior auth for keratoconus, Imaavy has updated PA criteria, Vykoura added to step therapy, Starjemza becomes preferred ustekinumab product, and Adstiladrin PA management moved to OncoHealth.
Action Required
REQUIREMENTS:
By July 15, 2026 (before 8/1/2026 effective date):
- Billing team: Update billing system to remove age restrictions from Vyjuvek (J3401) coverage rules. System should now accept pediatric and adult claims of all ages when dystrophic epidermolysis bullosa diagnosis is present.
- Billing team: Update Zolgensma (J3399) prior authorization templates to require provider documentation confirming member has NOT received prior gene therapy for spinal muscular atrophy (including Zolgensma or Itvisma). Flag claims without this documentation for denial.
- Update encounter forms and clinical checklist in EMR to prompt providers for gene therapy history before Zolgensma ordering.
By September 15, 2026 (before 10/1/2026 effective date):
- Billing team: Remove prior authorization requirement from Epioxa (J2789) billing rules. System should auto-approve claims when keratoconus diagnosis code is present; no manual PA review needed.
- Billing team: Update Imaavy prior authorization criteria in system to require documentation of: MGFA Clinical Classification Class II-IV generalized myasthenia gravis, MG-ADL score ≥6, and refractory disease status. Request updated Medical Necessity Guidelines from Point32Health for specific refractory disease criteria.
- Billing team: Add Vykoura to Medical Benefit Step Therapy logic. Configure system to require step therapy documentation per updated MNG.
- Billing team: Update Targeted Immunomodulators coverage rules: Set Starjemza (ustekinumab-hmny) as preferred ustekinumab product. Configure system to require prior authorization denials for Yesintek unless documentation shows trial-and-failure of Starjemza or clinical rationale for continuation.
- Billing team: Configure system to route all Adstiladrin (J9029) prior authorizations for Harvard Pilgrim Commercial and Tufts Medicare Preferred through OncoHealth vendor portal; discontinue internal PA review. Document OncoHealth contact information in billing team procedures.
Consequences of inaction: Claims for Vyjuvek and Zolgensma without proper documentation will be denied. Epioxa claims will be improperly held for PA review. Imaavy authorizations may be denied for insufficient documentation. Yesintek claims may be approved inappropriately. Adstiladrin authorizations routed internally instead of OncoHealth will be delayed or denied.